Series: "Update on tuberculosis" - Tuberculosis and noncommunicable diseases: Neglected links and missed opportunities

European Respiratory Journal

Volumn 37, Issue 5, 2011, Pages 1269-1282

  Creswell, J ^a   Raviglione, M ^a   Ottmani, S ^a   Migliori, G B ^b   Uplekar, M ^a   Blanc, L ^a   Sotgiu, G ^c   Lonnroth K ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b IRCCS   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Alcohol; Diabetes; Malnutrition; Noncommunicable disease; Smoking; Tuberculosis

Indexed keywords

GLIPIZIDE; ISONIAZID; RIFAMPICIN;

ALCOHOL CONSUMPTION; ALCOHOLISM; AWARENESS; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH PROGRAM; HOST RESISTANCE; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG TUBERCULOSIS; MALNUTRITION; MENTAL DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SILICOSIS; SMOKING; SOCIAL STATUS; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TUBERCULOSIS CONTROL; DRINKING BEHAVIOR; ECONOMICS; EUROPE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SCREENING; TREATMENT OUTCOME;

ALCOHOL DRINKING; DIABETES MELLITUS; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MALNUTRITION; MASS SCREENING; RISK FACTORS; SMOKING; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 79955657437     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00084310     Document Type: Review

References (148)

1. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112: 3547-3553. (Pubitemid 43739531)
2. Miranda JJ, Kinra S, Casas JP, et al. Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. Trop Med Int Health 2008; 13: 1225-1234.
3. Mayosi BM, Flisher AJ, Lalloo UG, et al. The burden of noncommunicable diseases in South Africa. Lancet 2009; 374: 934-947.
4. Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370: 1929-1938. (Pubitemid 350192633)
5. Ramaraj R, Alpert JS. Indian poverty and cardiovascular disease. Am J Cardiol 2008; 102: 102-106.
6. van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010; 35: 27-33.
7. Slama K. Global perspective on tobacco control. Part I. The global state of the tobacco epidemic. Int J Tuberc Lung Dis 2008; 12: 3-7.
8. Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health 2009; 6: 209-224.
9. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med 2007; 356: 213-215. (Pubitemid 46143224)
10. Rahman A, Prince M. Mental health in the tropics. Ann Trop Med Parasitol 2009; 103: 95-110.
11. Patel V. Mental health in low- and middle-income countries. Br Med Bull 2007; 81-82: 81-96. (Pubitemid 351194482)
12. Patel V, Araya R, Chatterjee S, et al. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 2007; 370: 991-1005. (Pubitemid 47384829)
13. World Health Organization. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Final Report of the Commission on Social Determinants of Health. Geneva, World Health Organization, 2008.
14. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 2008; 5: e152.
15. Lönnroth K, Williams BG, Stadlin S, et al. Alcohol use as a risk factor for tuberculosis: a systematic review. BMC Public Health 2008; 8: 289.
16. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and metaanalysis. PLoS Medicine 2007; 4: e142.
17. Cegielski P, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8: 286-298. (Pubitemid 38624865)
18. Lönnroth K, Castro K, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010; 375: 1814-1829.
19. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, World Health Organization, 2009.
20. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
21. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
22. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDRTB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
23. World Health Organization. Global Tuberculosis Control: A Short Update to the 2009 Report. Geneva, World Health Organization, 2009.
24. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021. (Pubitemid 36548927)
25. World Health Organization. Interim Policy on Collaborative TB/ HIV Activities. Geneva, World Health Organization, 2004.
26. Friedland G, Harries A, Coetzee D. Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. J Infect Dis 2007; 196: Suppl. 1, S114-S123. (Pubitemid 47206090)
27. Coker R, McKee M, Atun R, et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006; 332: 85-87. (Pubitemid 43099249)
28. Tocque K, Bellis MA, Beeching NJ, et al. A case-control study of lifestyle risk factors associated with tuberculosis in Liverpool, North-West England. Eur Respir J 2001; 18: 959-964. (Pubitemid 34092869)
29. Lönnroth K, Williams BG, Stadlin S, et al. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008; 8: 289.
30. World Health Organization. World Health Statistics 2008. Geneva, World Health Organization, 2008.
31. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
32. Blas E, Sivasankara AK, eds. Priority Public Health Conditions: From Learning to Action on Social Determinants of Health. Geneva, World Health Organization, 2010.
33. Szabo G. Alcohol and susceptibility to tuberculosis. Alcohol Health Res World 1997; 21: 39-41. (Pubitemid 127709481)
34. WHO Expert Committee on Problems Related to Alcohol Consumption: Second Report. In WHO Technical Report Series 944. Geneva, World Health Organization, 2007.
35. Mellencamp M. Effects of ethanol consumption on susceptibility to pulmonary and gastrointestinal infections. Alcohol Clin Exp Res 1996; 20: 192-195.
36. Szabo G. Alcohol's contribution to compromised immunity. Alcohol Health Res World 1997; 21: 30-41.
37. Houtmeyers E, Gosselink R, Gayan-Ramirez G, et al. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13: 1177-1188. (Pubitemid 29288948)
38. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 202, 2: 372-377.
39. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor a7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388. (Pubitemid 36157937)
40. World Health Organization, International Union Against Tuberculosis and Lung Disease, World Diabetes Foundation. Report from the Expert Meeting on Tuberculosis and Diabetes Mellitus. Geneva, World Health Organization, 2009.
41. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health 2009; 9: 450.
42. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733-743.
43. Sweetland A, Acha J, Guerra D. Enhancing adherence: the role of group psychotherapy in the treatment of MDR-TB in urban Peru. In: Cohen A, Kleinman A, Saraceno B, eds. World Mental Health Casebook: Social and Mental Health Programmes in Low- Income Countries. New York, Kluwer Academic Press, 2002; pp. 57-85.
44. Lönnroth K, Raviglione M. Global Epidemiology of Tuberculosis: Prospects for Control. Semin Respir Crit Care Med 2008; 29: 481-491.
45. Chakrabarti B, Calverley P, Davies P. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J COPD 2007; 2: 263-272. (Pubitemid 350110899)
46. Barboza CE, Winter DH, Seiscento M, et al. Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis. J Bras Pneumol 2008; 34: 961-968.
47. Stevenson CR, Critchley JA, Forouhi NG, et al. Diabetes and the risk of tuberculosis: a neglected threat to public health. Chronic Ill 2007; 3: 228-245. (Pubitemid 351927860)
48. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746.
49. Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.
50. Guler M, Unsal E, Dursun B, et al. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007; 61: 231-235.
51. Wada M. [The effectiveness of pyrazinamide-containing sixmonth short course chemotherapy]. Kekkaku 2000; 75: 665-673.
52. Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009; 137: 203-210.
53. Dooley KE, Tang T, Golub JE, et al. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009; 80: 634-639.
54. Maalej S, Belhaoui N, Bourguiba M, et al. [Pulmonary tuberculosis and diabetes. A retrospective study of 60 patients in Tunisia]. Presse Med 2009; 38: 20-24.
55. Mboussa J, Monabeka H, Kombo M, et al. [Course of pulmonary tuberculosis in diabetics]. Rev Pneumol Clin 2003; 59: 39-44.
56. Mellencamp M. Symposium: Effects of ethanol consumption on susceptibility to pulmonary and gastrointestinal infections. Alcohol Clin Exp Res 1996; 20: 192-195.
57. Rieder H. Epidemiologic basis of tuberculosis control. Paris, International Union Against Tuberculosis and Lung Disease, 1999.
58. Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis 2007; 11: 1049-1106.
59. Houtmeyers E, Gosselink R, Gayan-Ramirez G, et al. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13: 1177-1188. (Pubitemid 29288948)
60. Inghammar M, Ekbom A, Engström G, et al. COPD and the risk of tuberculosis - a population-based cohort study. PLoS One 2010; 5: e10138.
61. Lam KB, Jiang CQ, Jordan RE, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010; 137: 593-600.
62. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989; 83: 195-198. (Pubitemid 19207193)
63. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276. (Pubitemid 32378468)
64. Snider GL, Doctor L, Demas TA, et al. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 1971; 103: 625-640.
65. Leyton GB. Effects of slow starvation. Lancet 1946; 2: 253-255.
66. McKeown T, Brown RG. Medical evidence related to English population changes in the eighteenth century. Population Studies 1955; ix: 119-141.
67. McKeown T, Record RG. Reasons for the decline of mortality in England and Wales during the nineteenth century. Population Studies 1962; xvi: 94-122.
68. Lönnroth K, Williams BG, Cegielski P, et al. A consistent loglinear relationship between tuberculosis incidence and bodymass index. Int J Epidemiology 2010; 39: 149-155.
69. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007; 167: 1297-1304. (Pubitemid 46998502)
70. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
71. Kim DK, Kim HJ, Kwon SY, et al. Nutritional deficit as a negative prognostic factor in patients with miliary tuberculosis. Eur Respir J 2008; 32: 1031-1036.
72. Khan A, Sterling TR, Reves R, et al. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med 2006; 174: 344-348. (Pubitemid 44156615)
73. Rees D, Murray J. Silica, silicosis and tuberculosis. Int J Tuberc Lung Dis 2007; 11: 474-484. (Pubitemid 46732632)
74. Hnizdo E, Murray J. Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners. Occup Environ Med 1998; 55: 496-502. (Pubitemid 28335394)
75. teWaternaude JM, Ehrlich RI, Churchyard GJ, et al. Tuberculosis and silica exposure in South African gold miners. Occup Environ Med 2006; 63: 187-192.
76. Calvert GM, Rice FL, Boiano JM Sheehy JW, et al. Occupational silica exposure and risk of various diseases: an analysis using death certificates from 27 states of the United States. Occup Environ Med 2003; 60: 122-129. (Pubitemid 36157372)
77. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712. (Pubitemid 30650029)
78. Murray J, Sonnenberg P, Shearer S, et al. Drug resistant pulmonary tuberculosis in a cohort of southern African gold miners with a high prevalence of HIV infection. S Afr Med J 2000; 90: 381-386. (Pubitemid 30303556)
79. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet 2007; 370: 859-877. (Pubitemid 47371145)
80. Aghanwa HS, Erhabor GE. Demographic/socioeconomic factors in mental disorders associated with tuberculosis in southwest Nigeria. J Psychosom Res 1998; 45: 353-60. (Pubitemid 28448738)
81. Carta MG, Coppo P, Carpiniello B, et al. Mental disorders and health care seeking in Bandiagara: a community survey in the Dogon Plateau. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 222-229. (Pubitemid 27258655)
82. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101: S76-S88.
83. Levinsky L. Tuberculosis and cardiopulmonary failure. Dis Chest 1961; 40: 564-571.
84. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41: Suppl. 3, S199-S203.
85. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
86. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and rheumatism 2007; 57: 756-761. (Pubitemid 46932080)
87. Al Shohaib S. Tuberculosis in chronic renal failure in Jeddah. J Infect 2000; 40: 150-153. (Pubitemid 30312553)
88. Abdelrahman M, Sinha AK, Karkar A. Tuberculosis in end-stage renal disease patients on hemodialysis. Hemodial Int 2006; 10: 360-364. (Pubitemid 44489920)
89. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, World Health Organization, 2007.
90. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-955.
91. Me'emary F, Ottmani SE, Pio A, et al. Results of the feasibility test of the Practical Approach to Lung Health in the Syrian Arab Republic. East Mediterr Health J 2009; 15: 504-515.
92. Camacho M, Nogales M, Manjon R, et al. Results of PAL feasibility test in primary health care facilities in four regions of Bolivia. Int J Tuberc Lung Dis 2007; 11: 1246-1252. (Pubitemid 350146308)
93. Brimkulov N, Ottmani SE, Pio A, et al. Feasibility test results of the Practical Approach to Lung Health in Bishkek, Kyrgyzstan. Int J Tuberc Lung Dis 2009; 13: 533-539.
94. World Health Organization. Practical Approach to Lung Health - Manual on initiating PAL implementation. Geneva, World Health Organization, 2008.
95. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-1692.
96. Shafey O, Dolwick S, Guindon GE, eds. Tobacco Control Country Profiles 2003. 2nd Edn. Atlanta, American Cancer Society, 2003.
97. World Health Organization. WHO Global Status Report on Alcohol 2004. Geneva, World Health Organization, 2004.
98. Alberg AJ. Cigarette smoking: health effects and control strategies. Drugs Today 2008; 44: 895-904.
99. Kimerling ME, Shakes CF, Carlisle R, et al. Spot sputum screening: evaluation of an intervention in two homeless shelters. Int J Tuberc Lung Dis 1999; 3: 613-619. (Pubitemid 29336578)
100. Barry MA, Wall C, Shirley L, et al. Tuberculosis screening in Boston's homeless shelters. Public Health Rep 1986; 101: 487-494. (Pubitemid 16008885)
101. Goldgrub N, Santos LAR, Galesi VMN. Active case finding campaign in homeless shelters in Sao Paulo City, Brazil. Int J Tuberc Lung Dis 2002; 6: Suppl. 1, S153.
102. Galesi VMN, Almeida MMMB, Santos LAR. Tuberculosis casefinding campaign, Sao Paulo, Brazil. Int J Tuberc Lung Dis 2001; 5: S91-S92.
103. Diez M, Bleda MJ, Alcaide J. Determinants of health system delay among confirmed tuberculosis cases in Spain. Eur J Public Health 2005; 15: 343-349. (Pubitemid 41344532)
104. Snider DE. The relationship between tuberculosis and silicosis. Am Rev Respir Dis 1978; 118: 455-460.
105. Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman JG, Measham AR, et al. eds. Disease Control Priorities in Developing Countries. 2nd Edn. New York, Oxford University Press, 2006. pp. 289-309.
106. Laxminarayan R, Klein E, Dye C, et al. Economic Benefit of Tuberculosis Control. World Bank Policy Research Working Paper No. 4295. New York, World Bank, 2007.
107. Baily GVJ, Savic D, Gothi G D, et al. Potential yield of pulmonary tuberculosis cases by direct microscopy of sputum in a district of South India. Bull World Health Org 1967; 37: 875-892.
108. Golub JE, Mohan CI, Comstock GW, et al. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005; 9: 1183-1203. (Pubitemid 41735596)
109. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd Edn. The Hague, Tuberculosis Coalition for Technical Assistance, 2009.
110. Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1845.
111. Gelmanova IY, Keshavjee S, Golubchikova VT, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711. (Pubitemid 47416722)
112. Koriakin VA, Sokolova GB, Grinchar NA, et al. [Pharmacokinetics of isoniazid in patients with pulmonary tuberculosis and alcoholism.] Probl Tuberk 1986; 12: 43-46.
113. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006; 43: 848-854. (Pubitemid 44435511)
114. Thompson NP, Caplin ME, Hamilton MI, et al. Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388.
115. Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136. (Pubitemid 26060649)
116. Janssens B, Van Damme W, Raleigh B, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ 2007; 85: 880-885. (Pubitemid 350086461)
117. Laserson KF, Wells CD. Reaching the targets for tuberculosis control: the impact of HIV. Bull World Health Organ 2007; 85: 377-381. (Pubitemid 46718363)
118. Maher D, Harries AD, Zachariah R, et al. A global framework for action to improve the primary care response to chronic noncommunicable diseases: a solution to a neglected problem. BMC Public Health 2009; 9: 355.
119. 40th Union World Conference on Lung Health, Cancun, Mexico, 2009.
120. Brostrom R. Integrating Diabetes and TB Programs. www.nationaltbcenter. ucsf.edu/training/webarchive/tbdm/docs/CNTC-TBDM-Dec1009-Richard-Brostrom- Handout.pdf Date last accessed: February 9, 2011. Date last updated: December 10, 2009.
121. Wilk AI, Jensen NM, Havighurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med 1997; 12: 274-283. (Pubitemid 27212772)
122. Poikolainen K. Effectiveness of brief interventions to reduce alcohol intake in primary health care populations: a metaanalysis. Prev Med 1999; 28: 503-509. (Pubitemid 29370286)
123. Room R, Babor T, Rehm J. Alcohol and public health: a review. Lancet 2005; 365: 519-530.
124. Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse. An evidenced based review. Weinheim, Wiley, 2003.
125. Nolen-Hoeksema S. Gender differences in risk factors and consequences for alcohol use and problems. Clin Psychol Rev 2004; 24: 981-1010. (Pubitemid 40247305)
126. Batty GD, Lewars H, Emslie C. Internationally recognized guidelines for "sensible" alcohol consumption: is exceeding them actually detrimental to health and social circumstances? Evidence from a population-based cohort study. J Public Health 2009; 31: 360-336.
127. International Union Against Tuberculosis and Lung Disease, World Health Organization. A WHO/The Union monograph on TB and tobacco control - joining efforts to control two related global epidemics. Geneva, World Health Organization, 2007.
128. Solberg LI, Maciosek MV, Edwards NM, et al. Repeated tobaccouse screening and intervention in clinical practice. Health impact and cost effectiveness. Am J Prev Med 2006; 31: 62-71.
129. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD000165.
130. El Sony A, Slama K, Salieh M, et al. Feasibility of brief tobacco cessation advice for tuberculosis patients: a study from Sudan. Int J Tuberc Lung Dis 2007; 11: 150-155. (Pubitemid 46219277)
131. Abba K, Sudarsanam TD, Grobler L, et al. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 2008; 4: CD006086.
132. Jamieson C, Norton B, Day T, et al. The quantitative effect of nutrition support on quality of life in outpatients. Clinical Nutrition 1997; 16: 25-28.
133. Lettow MV, Kumwenda JJ, Harries AD, et al. Malnutrition and the severity of lung disease in adults with pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 2004; 8: 211-217. (Pubitemid 38622929)
134. Papathakis P, Piwoz E. Nutrition and Tuberculosis: A Review of the Literature and Considerations for TB Control Programs. Washington, USAID, 2008.
135. Xie QM, Tang HF, Chen JQ, et al. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacol Sin 2002; 23: 1107-1113.
136. World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. Geneva, World Health Organization, 2006.
137. Rehm J, Greenfield TK. Public alcohol policy: current directions and new opportunities. Clin Pharmacol Ther 2008; 83: 640-643. (Pubitemid 351417067)
138. Babor T, Caetano R, Casswell S, et al. Alcohol: No Ordinary Commodity. Research and Public Policy. Oxford, Oxford University Press, 2003.
139. van den Berg M, van Baal PH, Tariq L, et al. The costeffectiveness of increasing alcohol taxes: a modeling study. BMC Med 2008; 6: 36.
140. Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1069-1075. (Pubitemid 32696251)
141. Arinaminpathy N, Dye C. Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe. J R Soc Interface 2010; 7: 1559-1569.
142. Oeltmann JE, Kammerer JS, Pevzner ES, et al. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009; 169: 189-197.
143. World Health Organization. WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, World Health Organization, 2008.
144. Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd Edn. San Francisco, Francis J. Curry National Tuberculosis Center, 2008.
145. World Health Organization. Global Tuberculosis Control 2009. Geneva, World Health Organization, 2009.
146. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet 2004; 363: 814-819. (Pubitemid 38315173)
147. Dye C, Watt CJ, Bleed DM, et al. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis 2003; 83: 35-43.
148. Corbett EL, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a clusterrandomised trial. Lancet 2010; 376: 1244-1253.